13th of August, 2023: We have reached our inclusion goal of 1420 patients! Inclusion will continue for 30 more days and end 12th of September, 2023 at hours 23:59 (CET)

22nd of March, 2023: We have included 1000 patients!

14th of March, 2023: The Data Monitoring and Safety Committee (DMSC) conducted the 2nd and final interim analysis of the trial and recommended that the trial should continue

6th of December, 2022: Inselspital University Hospital Bern started recruiting today!

2nd of November, 2022: The Ethics Committee in Switzerland has approved The TRAUMOX2 Trial at Bern University Hospital (Inselspital; INSEL)! We are looking forward to starting inclusion

24th of August, 2022: We have included 500 patients!

16th of May, 2022: We have included 200 patients!

16th of May, 2022: TRAUMOX2 started recruiting at Aarhus University Hospital (AUH), Aarhus

6th of May, 2022: TRAUMOX2 started recruiting at Erasmus MC, University Medical Center (EMC) in Rotterdam

10th of March, 2022: TRAUMOX2 started recruiting at Odense University Hospital (OUH), Odense

7th of February, 2022: 50 patients have been included!

23rd of December, 2021: 10 patients have been included!

7th of December, 2021: TRAUMOX2 started recruiting at Rigshospitalet, Copenhagen

20th of October, 2021The Danish Research Ethics Committee has approved TRAUMOX2 at all Danish sites (journal number: H-21018062)

16th of April, 2021: Approval was given by the Danish Medicines Agency (EudraCT number: 2021-000556-19)

12th of March, 2021: Approval applications are sent to the Danish Research Ethics Committee and the Danish Medicines Agency